← Leaderboards
Scott Hiebert
Vanderbilt University
$33,340,607
Attributed
$33,340,607
Total exposure
19
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.5M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$33,340,607 · 19
By mechanism
R01$24,219,602 · 10
T32$5,603,751 · 1
P50$2,606,927 · 2
P30$903,327 · 5
R13$7,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Michael E Engel$2,768,546
- Emily Hodges$2,422,418
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsChimeric ProteinsGenesPhenotypeAffectGene ExpressionHistonesGenetic TranscriptionChromosomal TranslocationMediatingTranscription FactorIn VivoTrainingAnticancer ResearchComplexEnzymesCbfa2t1 GeneProgramsFamily MemberRecruitment ActivityTumorGene RepressionLinkDna Binding Domain
Grant awards (103)
Role of PRC1 in RUNX1-ETO-mediated transcriptional control$409,964
R01 · FY2024 · CA · contact PI
Biochemical and Chemical Training for Cancer Research$374,943
T32 · FY2024 · CA · contact PI
Flow Cytometry Shared Resource$126,489
P30 · FY2024 · CA · contact PI
Role of PRC1 in RUNX1-ETO-mediated transcriptional control$422,612
R01 · FY2023 · CA · contact PI
Biochemical and Chemical Training for Cancer Research$370,188
T32 · FY2023 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$169,288
P30 · FY2023 · CA · contact PI
Flow Cytometry Shared Resource$126,489
P30 · FY2023 · CA · contact PI
Role of PRC1 in RUNX1-ETO-mediated transcriptional control$422,895
R01 · FY2022 · CA · contact PI
Establishing that Hdac3 is a therapeutic target in a subset of B cell Lymphoma$382,774
R01 · FY2022 · CA · contact PI
Biochemical and Chemical Training for Cancer Research$302,048
T32 · FY2022 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$169,288
P30 · FY2022 · CA · contact PI
Flow Cytometry Shared Resource$126,489
P30 · FY2022 · CA · contact PI
Role of PRC1 in RUNX1-ETO-mediated transcriptional control$457,157
R01 · FY2021 · CA · contact PI
Establishing that Hdac3 is a therapeutic target in a subset of B cell Lymphoma$390,586
R01 · FY2021 · CA · contact PI
Biochemical and Chemical Training for Cancer Research$328,873
T32 · FY2021 · CA · contact PI
Establishing that Hdac3 is a therapeutic target in a subset of B cell Lymphoma$390,586
R01 · FY2020 · CA · contact PI
Biochemical and Chemical Training for Cancer Research$312,906
T32 · FY2020 · CA · contact PI
Establishing that Hdac3 is a therapeutic target in a subset of B cell Lymphoma$382,280
R01 · FY2019 · CA · contact PI
Biochemical and Chemical Training for Cancer Research$367,802
T32 · FY2019 · CA · contact PI
Establishing that Hdac3 is a therapeutic target in a subset of B cell Lymphoma$401,319
R01 · FY2018 · CA · contact PI
Biochemical and Chemical Training for Cancer Research$383,570
T32 · FY2018 · CA · contact PI
Regulation of transcription and tumor suppression by MTG family members$364,000
R01 · FY2018 · CA · contact PI
Role of AML1-ETO in Acute Leukemia$353,250
R01 · FY2018 · CA · contact PI
Regulation of transcription and tumor suppression by MTG family members$364,000
R01 · FY2017 · CA · contact PI
Role of AML1-ETO in Acute Leukemia$353,250
R01 · FY2017 · CA · contact PI
Biochemical and Chemical Training for Cancer Research$352,214
T32 · FY2017 · CA · contact PI
Biochemical and Chemical Training for Cancer Research$3,622
T32 · FY2017 · CA · contact PI
Career Developmental Program$2,033,881
P50 · FY2016 · CA · contact PI
Hdac3 as a therapeutic target in BCL6-dependent lymphoma$403,135
R01 · FY2016 · CA · contact PI
Regulation of transcription and tumor suppression by MTG family members$364,000
R01 · FY2016 · CA · contact PI
Role of AML1-ETO in Acute Leukemia$353,250
R01 · FY2016 · CA · contact PI
Biochemical and Chemical Training for Cancer Research$349,773
T32 · FY2016 · CA · contact PI
Hdac3 as a therapeutic target in BCL6-dependent lymphoma$403,135
R01 · FY2015 · CA · contact PI
Regulation of transcription and tumor suppression by MTG family members$364,000
R01 · FY2015 · CA · contact PI
Biochemical and Chemical Training for Cancer Research$355,797
T32 · FY2015 · CA · contact PI
Role of AML1-ETO in Acute Leukemia$353,250
R01 · FY2015 · CA · contact PI
Career Developmental Program$140,297
P50 · FY2015 · CA · contact PI
Developmental Research Program$118,291
P50 · FY2015 · CA · contact PI
Hdac3 as a therapeutic target in BCL6-dependent lymphoma$391,041
R01 · FY2014 · CA · contact PI
Regulation of transcription and tumor suppression by MTG family members$363,613
R01 · FY2014 · CA · contact PI
Inactivation of Hdac3 in the cause, prevention, and treatment of HCC$360,974
R01 · FY2014 · CA · contact PI
Role of AML1-ETO in Acute Leukemia$353,250
R01 · FY2014 · CA · contact PI
Biochemical and Chemical Training for Cancer Research$322,072
T32 · FY2014 · CA · contact PI
Career Developmental Program$57,455
P50 · FY2014 · CA · contact PI
Developmental Research Program$38,301
P50 · FY2014 · CA · contact PI
Hdac3 as a therapeutic target in BCL6-dependent lymphoma$378,957
R01 · FY2013 · CA · contact PI
Inactivation of Hdac3 in the cause, prevention, and treatment of HCC$350,997
R01 · FY2013 · CA · contact PI
Biochemical and Chemical Training for Cancer Research$340,026
T32 · FY2013 · CA · contact PI
Role of AML1-ETO in Acute Leukemia$289,099
R01 · FY2013 · CA · contact PI
Career Developmental Program$61,161
P50 · FY2013 · CA · contact PI
Developmental Research Program$40,772
P50 · FY2013 · CA · contact PI
FASEB SRC on HDACs, Sirtuins and Reversible Acetylation in Signaling and Disease$7,000
R13 · FY2013 · AG · contact PI
Hdac3 as a therapeutic target in BCL6-dependent lymphoma$404,499
R01 · FY2012 · CA · contact PI
Inactivation of Hdac3 in the cause, prevention, and treatment of HCC$374,701
R01 · FY2012 · CA · contact PI
Role of AML1-ETO in Acute Leukemia$307,553
R01 · FY2012 · CA · contact PI
Biochemical and Chemical Training for Cancer Research$292,046
T32 · FY2012 · CA · contact PI
Career Developmental Program$70,061
P50 · FY2012 · CA · contact PI
Developmental Research Program$46,708
P50 · FY2012 · CA · contact PI
Inactivation of Hdac3 in the cause, prevention, and treatment of HCC$375,240
R01 · FY2011 · CA · contact PI
Biochemical and Chemical Training for Cancer Research$320,299
T32 · FY2011 · CA · contact PI
Role of AML1-ETO in Acute Leukemia$307,553
R01 · FY2011 · CA · contact PI
Inactivation of Hdac3 in the cause, prevention, and treatment of HCC$385,869
R01 · FY2010 · CA · contact PI
Function of MTG16/ETO2 in acute leukemia$383,750
R01 · FY2010 · HL · contact PI
Role of AML1-ETO in Acute Leukemia$317,065
R01 · FY2010 · CA · contact PI
Biochemical and Chemical Training for Cancer Research$304,317
T32 · FY2010 · CA · contact PI
Mechanism of inv(16) mediated leukemogenesis$417,145
R01 · FY2009 · CA · contact PI
Function of MTG16/ETO2 in acute leukemia$383,750
R01 · FY2009 · HL · contact PI
Function of Myeloid Translocation Gene Related-1$329,190
R01 · FY2009 · CA · contact PI
Role of AML1-ETO in Acute Leukemia$317,065
R01 · FY2009 · CA · contact PI
Biochemical and Chemical Training for Cancer Research$273,252
T32 · FY2009 · CA · contact PI
Mechanism of inv(16) mediated leukemogenesis$405,438
R01 · FY2008 · CA · contact PI
Function of MTG16/ETO2 in acute leukemia$383,750
R01 · FY2008 · HL · contact PI
Function of Myeloid Translocation Gene Related-1$319,599
R01 · FY2008 · CA · contact PI
Biochemical and Chemical Training for Cancer Research$250,003
T32 · FY2008 · CA · contact PI
Mechanism of inv(16) mediated leukemogenesis$402,551
R01 · FY2007 · CA · contact PI
Function of MTG16/ETO2 in acute leukemia$383,450
R01 · FY2007 · HL · contact PI
Function of Myeloid Translocation Gene Related-1$316,436
R01 · FY2007 · CA · contact PI
Role of AML1-ETO in Acute Leukemia$302,817
R01 · FY2007 · CA · contact PI
Mechanism of inv(16) mediated leukemogenesis$402,839
R01 · FY2006 · CA · contact PI
Function of Myeloid Translocation Gene Related-1$315,368
R01 · FY2006 · CA · contact PI
Role of AML1-ETO in Acute Leukemia$311,860
R01 · FY2006 · CA · contact PI
Role of TEL and the t(12;21) in B cell ALL$295,271
R01 · FY2006 · CA · contact PI
Mechanism of inv(16) mediated leukemogenesis$424,845
R01 · FY2005 · CA
Role of AML1-ETO in Acute Leukemia$319,365
R01 · FY2005 · CA
Function of Myeloid Translocation Gene Related-1$311,504
R01 · FY2005 · CA
Role of TEL and the t(12;21) in B cell ALL$302,378
R01 · FY2005 · CA
MECHANISM OF INV(16) MEDIATED LEUKEMOGENESIS$450,237
R01 · FY2004 · CA
Role of AML1-ETO in Acute Leukemia$319,365
R01 · FY2004 · CA
Role of TEL and the t(12;21) in B cell ALL$302,378
R01 · FY2004 · CA
PROGRAM LEADERS$185,284
P30 · FY2004 · CA
MECHANISM OF INV(16) MEDIATED LEUKEMOGENESIS$444,551
R01 · FY2003 · CA
Role of AML1-ETO in Acute Leukemia$319,365
R01 · FY2003 · CA
Role of TEL and the t(12;21) in B cell ALL$302,378
R01 · FY2003 · CA
Role of TEL and the t(12;21) in B cell ALL$302,461
R01 · FY2002 · CA
AML1 AND AML/ETO IN DIFFERENTIATION AND ACUTE LEUKEMIA$292,307
R01 · FY2002 · CA
MECHANISM OF INV(16) MEDIATED LEUKEMOGENESIS$271,800
R01 · FY2002 · CA
TEL AND THE T(12--21) AND B CELL ALL$288,780
R01 · FY2001 · CA
AML1 AND AML/ETO IN DIFFERENTIATION AND ACUTE LEUKEMIA$283,793
R01 · FY2001 · CA
MECHANISM OF INV(16) MEDIATED LEUKEMOGENESIS$272,700
R01 · FY2001 · CA
TEL AND THE T(12--21) AND B CELL ALL$280,369
R01 · FY2000 · CA
AML1 AND AML/ETO IN DIFFERENTIATION AND ACUTE LEUKEMIA$275,527
R01 · FY2000 · CA
MECHANISM OF INV(16) MEDIATED LEUKEMOGENESIS$272,775
R01 · FY2000 · CA
E2F AND DIFFERENTIATION, APOPTOSIS, AND LEUKEMIA$216,591
R01 · FY2000 · AG